Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
- Chemical Structure - f205834f 7a27 4968 9605 90a2c53ce7e9 01
- Figure 1 - f205834f 7a27 4968 9605 90a2c53ce7e9 02
- Figure 2 - f205834f 7a27 4968 9605 90a2c53ce7e9 03
- Figure 3 - f205834f 7a27 4968 9605 90a2c53ce7e9 04
- Figure 4 - f205834f 7a27 4968 9605 90a2c53ce7e9 05
- image - f205834f 7a27 4968 9605 90a2c53ce7e9 06
- Company Logo - f205834f 7a27 4968 9605 90a2c53ce7e9 07
- Label - lbl721622506
Product Label Images
The following 8 images provide visual information about the product associated with Losartan Potassium NDC 72162-2506 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Chemical Structure - f205834f 7a27 4968 9605 90a2c53ce7e9 01
Figure 1 - f205834f 7a27 4968 9605 90a2c53ce7e9 02
This text provides data on the percentage of patients who reached the primary endpoint in a clinical trial comparing Atenolol and Losartan potassium. The adjusted risk reduction between the two treatments is reported as 13%, with a significance level of p=0.021. The timeline of the study is also shown with study months marked from 0 to 66.*
Figure 2 - f205834f 7a27 4968 9605 90a2c53ce7e9 03
This text provides information about two medications, Atenolol and Losarten potassium. The text also mentions an adjusted risk reduction of 25% with a p-value of 0.001. It further highlights the percentage of patients with fatal or non-fatal stroke over different study months.*
Figure 3 - f205834f 7a27 4968 9605 90a2c53ce7e9 04
This text appears to provide data on a study comparing the effects of Losartan and Atenolol on stroke outcomes in a population with different demographic and medical characteristics. The study includes details like the number of events, rates, and percentages in various subgroups based on age, gender, race, diabetes status, and history of cardiovascular disease. The results seem to suggest that Atenolol may have favored outcomes over Losartan. The analysis is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 - f205834f 7a27 4968 9605 90a2c53ce7e9 05
This text seems to show the results of a study comparing the effectiveness of Losartan Potassium versus a Placebo in reducing the risk of an event in patients. The study indicates that there was a 16.1% risk reduction with a p-value of 0.022. The data also shows that 9% of the patients with the event were impacted by the intervention.*
image - f205834f 7a27 4968 9605 90a2c53ce7e9 06
Company Logo - f205834f 7a27 4968 9605 90a2c53ce7e9 07
Label - lbl721622506
This is a description of a medication package insert for Losartan Potassium tablets, each containing 25 mg of the active ingredient. It provides information on dosage, storage conditions (20° to 25°C), and handling instructions. The package insert includes a QR code for dosage and patient information leaflet. The tablets are to be dispensed by a pharmacist and should be kept out of reach of children. The medication is manufactured by Unichem Laboratories Ltd. and repackaged by Bryant Ranch Prepack, Inc. in the USA.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
